Abstract
Malignant cutaneous tumors arising from epithelial cells, including malignant adnexal neoplasia, will be discussed in this chapter. Malignant melanoma that derives from epidermal melanocytes is the subject of another chapter. Basal cell carcinoma and squamous cell carcinoma are referred to as non–melanoma skin cancers. Both tumors compose the great majority of skin cancers and cause significant health concerns. Their morbidity can be significantly reduced with early diagnosis. Clinical features of these tumors will be discussed broadly. In addition, there are many types of malignant adnexal skin tumors including the ones with high metastatic potential. But all of them are rare. The classic non–melanoma skin cancers can usually be diagnosed with typical clinical features, but most malignant adnexal tumors present as nonspecific bizarre nodules, plaques, or ulcerations and are usually difficult to diagnose clinically. Additionally, Merkel cell carcinoma is also discussed in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Ang JM, Alai NN, Ritter KR, Machtinger LA. Muir-Torre syndrome: case report and review of the literature. Cutis. 2011;87:125–8.
Attili SK, Evans A, Fleming CJ. Recurrent pigmented eccrine porocarcinoma presenting as carcinoma erysipeloides. Clin Exp Dermatol. 2009;30;e493–5.
Brantsch KD, Meisner C, Schoenfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.
Burgdorf WHC, Plewig G, Wolff HH, Landthaler M. Braun-Falco’s dermatology, edn 3. Italy: Springer-Verlag; 2009.
Calonje JE, Brenn T, Lazar AJ, McKee PH. McKee’s pathology of the skin, edn 4. China: Elsevier; 2012.
Caputo R, Tadini G. Atlas of genodermatoses. Spain: Taylor and Francis; 2006.
Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol. 2012;22:299–309.
Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45:489–98.
Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265–72.
Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677–82.
James WD, Berger T, Elston D. Andrew’s diseases of the skin: Clinical Dermatology, edn 11. China: Saunders Elsevier; 2011.
Liu LS, Colegio OR. Molecularly targeted therapies for nonmelanoma skin cancers. Int J Dermatol. 2013;52:654–65.
Lortscher DN, Sengelmann RD, Allen SB. Acrochordon-like basal cell carcinomas in patients with basal cell nevus syndrome. Dermatol Online J. 2007;13:21.
Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer. Lancet. 2010;375:673–85.
Mougel F, Kanitakis J, Faure M, Euvrard S. Basosquamous cell carcinoma in organ transplant patients: a clinicopathologic study. J Am Acad Dermatol. 2012;66:e151–7.
Nehal KS, Levine VJ, Ashinof R. Basal cell carcinoma of the genitalia. Dermatol Surg. 1998;24:1361–3.
Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms–part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145–59.
Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562–8.
Renzi C, Mastroeni S, Passarelli F, et al. Factors associated with large cutaneous squamous cell carcinomas. J Am Acad Dermatol. 2010;63:404–11.
Rigel DS, Robinson JK, Ross M, Friedman RJ, Corkerell CJ, Lim HW, Stockfleth HW, Kirkwood JM. Cancer of the skin, edn 2. China: Saunders Elsevier; 2011.
Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710–20.
Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157:47–51.
Röwert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156:8–12.
Schwartz RA. Skin cancer: recognition and management, edn 2. Singapore: Blackwell Publishing; 2008.
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.
Shiohara J , Koga H, Uhara H, et al. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. J Dermatol. 2007;34:516–22.
Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180–8.
Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35–48.
Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143:264–8.
Weedon D. Weedon’s skin pathology, edn 3. China: Elsevier; 2010.
Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327:794–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Baykal, C., Yazganoğlu, K.D. (2014). Malignant Epithelial Tumors. In: Clinical Atlas of Skin Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40938-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-40938-7_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40937-0
Online ISBN: 978-3-642-40938-7
eBook Packages: MedicineMedicine (R0)